SAREPTA THERAPEUTICS INC

NASDAQ: SRPT (Sarepta Therapeutics, Inc.)

Last update: 3 days ago, 8:58PM

20.18

-0.81 (-3.86%)

  • 1D -3.86%
  • 5D 7.34%
  • 1M 48.16%
  • 6M -80.88%
  • YTD -83.74%
  • 1Y -85.73%
  • 5Y -85.71%
Previous Close 20.99
Open 21.01
Volume 5,402,369
Avg. Volume (3M) 11,796,788
Market Cap 1,971,856,384
Price / Earnings (Forward) 9.84
Price / Sales 0.930
Price / Book 1.51
52 Weeks Range
10.42 (-48%) — 144.22 (614%)
Earnings Date 5 Nov 2025
Profit Margin -11.12%
Operating Margin (TTM) -40.33%
Diluted EPS (TTM) -2.64
Quarterly Revenue Growth (YOY) 80.20%
Quarterly Earnings Growth (YOY) 248.40%
Total Debt/Equity (MRQ) 118.73%
Current Ratio (MRQ) 4.02
Operating Cash Flow (TTM) -547.15 M
Levered Free Cash Flow (TTM) -741.26 M
Return on Assets (TTM) -2.19%
Return on Equity (TTM) -23.61%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bearish
Biotechnology (Global) Mixed Bearish
Stock Sarepta Therapeutics, Inc. Bearish Bearish

AIStockmoo Score

0.6
Analyst Consensus -3.5
Insider Activity NA
Price Volatility 0.5
Technical Moving Averages 3.5
Technical Oscillators 2.0
Average 0.63

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
SRPT 2 B - - 1.51
RVMD 7 B - - 3.66
PTCT 4 B - 6.92 -
OCUL 2 B - - 7.14
NVAX 2 B - 4.29 41.92
ZYME 1 B - - 3.25

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Sector Healthcare
Industry Biotechnology
Investment Style Small Core
% Held by Insiders 4.42%
% Held by Institutions 96.33%

Ownership

Name Date Shares Held
Exome Asset Management Llc 30 Jun 2025 2,000,000
Erste Asset Management Gmbh 30 Jun 2025 1,621,415
52 Weeks Range
10.42 (-48%) — 144.22 (614%)
Price Target Range
7.00 (-65%) — 80.00 (296%)
High 80.00 (Scotiabank, 296.43%) Buy
Median 20.00 (-0.89%)
Low 7.00 (Citigroup, -65.31%) Sell
Average 26.38 (30.72%)
Total 5 Buy, 12 Hold, 4 Sell
Avg. Price @ Call 17.80
Firm Date Target Price Call Price @ Call
B of A Securities 21 Aug 2025 16.00 (-20.71%) Sell 20.18
20 Aug 2025 17.00 (-15.76%) Sell 20.18
Deutsche Bank 15 Aug 2025 12.00 (-40.54%) Sell 21.81
17 Jun 2025 25.00 (23.89%) Hold 21.56
Goldman Sachs 07 Aug 2025 19.00 (-5.85%) Hold 17.96
17 Jun 2025 29.00 (43.71%) Hold 21.56
Wells Fargo 07 Aug 2025 50.00 (147.77%) Buy 17.96
24 Jul 2025 48.00 (137.86%) Buy 12.88
Barclays 30 Jul 2025 22.00 (9.02%) Hold 16.75
29 Jul 2025 22.00 (9.02%) Hold 15.83
BMO Capital 29 Jul 2025 50.00 (147.77%) Hold 15.83
22 Jul 2025 25.00 (23.89%) Hold 13.62
Bernstein 29 Jul 2025 13.00 (-35.58%) Hold 15.83
JP Morgan 29 Jul 2025 24.00 (18.93%) Hold 15.83
21 Jul 2025 20.00 (-0.89%) Buy 13.32
Morgan Stanley 29 Jul 2025 20.00 (-0.89%) Hold 15.83
17 Jun 2025 40.00 (98.22%) Hold 21.56
Oppenheimer 29 Jul 2025 37.00 (83.35%) Buy 15.83
18 Jul 2025 41.00 (103.17%) Buy 14.08
Piper Sandler 29 Jul 2025 15.00 (-25.67%) Hold 15.83
22 Jul 2025 11.00 (-45.49%) Hold 13.62
Citigroup 24 Jul 2025 7.00 (-65.31%) Sell 12.88
Jefferies 24 Jul 2025 35.00 (73.44%) Buy 12.88
16 Jun 2025 54.00 (167.59%) Buy 20.94
Leerink Swann 21 Jul 2025 10.00 (-50.45%) Hold 13.32
Mizuho 21 Jul 2025 14.00 (-30.62%) Hold 13.32
18 Jun 2025 40.00 (98.22%) Buy 20.77
UBS 21 Jul 2025 12.00 (-40.54%) Hold 13.32
Needham 18 Jul 2025 50.00 (147.77%) Hold 14.08
17 Jul 2025 50.00 (147.77%) Buy 21.97
Baird 17 Jul 2025 35.00 (73.44%) Buy 21.97
17 Jun 2025 30.00 (48.66%) Buy 21.56
RBC Capital 17 Jul 2025 23.00 (13.97%) Hold 21.97
HC Wainwright & Co. 25 Jun 2025 10.00 (-50.45%) Sell 17.46
16 Jun 2025 10.00 (-50.45%) Sell 20.94
Scotiabank 06 Jun 2025 80.00 (296.43%) Buy 43.01
Show more

No data within this time range.

  • 3M
Date Type Details
22 Aug 2025 Announcement Latest SueWallSt Podcast: What SRPT Investors Need to Know About the Lawsuit
22 Aug 2025 Announcement Investors SueWallSt as Sarepta Therapeutics, Inc. Faces Securities Fraud Allegations
21 Aug 2025 Announcement SueWallSt Podcast Series Launches With Focus on Sarepta Therapeutics, Inc. (SRPT) Fraud Allegations
21 Aug 2025 Announcement Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027
18 Aug 2025 Announcement SueWallSt Podcast Explains Class Action Against Sarepta Therapeutics, Inc. (SRPT)
13 Aug 2025 Announcement Shareholders SueWallSt in New Class Action Against Sarepta Therapeutics, Inc. - Act Now
13 Aug 2025 Announcement Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment
12 Aug 2025 Announcement New SueWallSt Podcast Covers Sarepta Therapeutics, Inc. (SRPT) Class Action
12 Aug 2025 Announcement Shareholders SueWallSt in New Class Action Against Sarepta Therapeutics, Inc. - Act Now
06 Aug 2025 Announcement Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments
31 Jul 2025 Announcement Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results
28 Jul 2025 Announcement Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics
28 Jul 2025 Announcement FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals With Duchenne Muscular Dystrophy
25 Jul 2025 Announcement Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union
25 Jul 2025 Announcement Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS
21 Jul 2025 Announcement Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.
21 Jul 2025 CNBC FDA taps biotech industry veteran as RFK Jr.'s top drug regulator 
18 Jul 2025 Announcement Sarepta Therapeutics Provides Statement on ELEVIDYS
18 Jul 2025 CNBC Sarepta shares plunge 40% as future of its gene therapy appears at risk
16 Jul 2025 Announcement Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label
26 Jun 2025 Announcement Shamis & Gentile, P.A. Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Sarepta Therapeutics, Inc. Securities and Sets a Lead Plaintiff Deadline of August 25, 2025
15 Jun 2025 Announcement Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
04 Jun 2025 Announcement U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria